Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 1
2014 1
2016 1
2018 1
2021 1
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
[Diabetes by immunotherapy].
Manzano N, Ocampo P, Nicolini C, Halac S, Aguirre M, Rivero S, Zylberman M. Manzano N, et al. Among authors: rivero s. Medicina (B Aires). 2018;78(1):60. Medicina (B Aires). 2018. PMID: 29360082 Free article. Spanish. No abstract available.
HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks.
Mandó P, Waisberg F, Pasquinelli R, Rivero S, Ostinelli A, Perazzo F. Mandó P, et al. Among authors: rivero s. Onco Targets Ther. 2023 Feb 19;16:115-132. doi: 10.2147/OTT.S335934. eCollection 2023. Onco Targets Ther. 2023. PMID: 36844609 Free PMC article. Review.
Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates.
González-Hurtado D, Rivero S, Samamé Pérez-Vargas JC, Petracci FE. González-Hurtado D, et al. Among authors: rivero s. Breast Cancer (Auckl). 2023 Aug 23;17:11782234231192780. doi: 10.1177/11782234231192780. eCollection 2023. Breast Cancer (Auckl). 2023. PMID: 37637230 Free PMC article. Review.
The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review.
Narvaez D, Nadal J, Nervo A, Costanzo MV, Paletta C, Petracci FE, Rivero S, Ostinelli A, Freile B, Enrico D, Pombo MT, Amat M, Aguirre ED, Chacon M, Waisberg F. Narvaez D, et al. Among authors: rivero s. Cancers (Basel). 2024 Jan 17;16(2):396. doi: 10.3390/cancers16020396. Cancers (Basel). 2024. PMID: 38254885 Free PMC article. Review.
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
Bruno L, Ostinelli A, Waisberg F, Enrico D, Ponce C, Rivero S, Blanco A, Zarba M, Loza M, Fabiano V, Amat M, Pombo MT, Noro L, Chacón M, Coló F, Chacón R, Nadal J, Nervo A, Costanzo V. Bruno L, et al. Among authors: rivero s. JCO Precis Oncol. 2022 Mar;6:e2100140. doi: 10.1200/PO.21.00140. JCO Precis Oncol. 2022. PMID: 35235412
LuciA-15 - a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and/or somatic mutation of BRCA genes or homologous recombination repair related genes.
Petracci FE, Villarreal-Garza C, Argañaraz F, Abuin GG, Peñaloza J, Flores MA, Piazzoni L, Riggi C, Fabiano L, González L, Cieplinski B, Rivero S, Korbenfeld E, Mandó P. Petracci FE, et al. Among authors: rivero s. Ecancermedicalscience. 2023 Nov 21;17:1634. doi: 10.3332/ecancer.2023.1634. eCollection 2023. Ecancermedicalscience. 2023. PMID: 38414929 Free PMC article.
The role of modern parameters and their relationship with recurrence risk as assessed by Oncotype DX: real-world evidence.
Narvaez D, Nadal J, Nervo A, Costanzo V, Paletta C, Petracci F, Rivero S, Ostinelli A, Coló F, Martín L, Fabiano V, Sabatini L, Perazzolo A, Amat M, Chacon M, Waisberg F. Narvaez D, et al. Among authors: rivero s. Ecancermedicalscience. 2024 Feb 6;18:1664. doi: 10.3332/ecancer.2024.1664. eCollection 2024. Ecancermedicalscience. 2024. PMID: 38439804 Free PMC article.
13 results